SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: 424B5
Document Type: 424B5
Date Filed: 2025-12-09
Accession Number: 0001213900-25-119671
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025119671/ea0268926-424b5_synergy.htm

Chunk 22 of 23
Word Count: 1367
Character Count: 8545

Document Content:

adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper. NRS Section 78.747 provides that except as otherwise provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability of the corporation, unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine the question of whether a director or officer acts as the alter ego of a corporation.

Our amended and restated bylaws
provide that we will indemnify our directors, officers, employees and agents to the extent and in the manner permitted by the provisions
of the NRS, as amended from time to time, subject to any permissible expansion or limitation of such indemnification, as may be set forth
in any stockholders’ or directors’ resolution or by contract. Any repeal or modification of these provisions approved by our
stockholders will be prospective only and will not adversely affect any limitation on the liability of any of our directors or officers
existing as of the time of such repeal or modification. We are also permitted to apply for insurance on behalf of any director, officer,
employee or other agent for liability arising out of his actions, whether or not the NRS would permit indemnification.

We have entered into agreements
with our officers and directors that provide contractual indemnification in addition to the indemnification provided for in our articles
of incorporation and amended and restated bylaws.

We do not currently carry directors’
and officers’ insurance. However, we may in the future purchase a policy of directors’ and officers’ liability insurance
that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures
us against our obligations to indemnify our officers and directors.

These provisions may discourage
stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. These provisions also may have the effect
of reducing the likelihood of derivative litigation against officers and directors, even though such an action, if successful, might otherwise
benefit us and our stockholders. Furthermore, a stockholder’s investment may be adversely affected to the extent we pay the costs
of settlement and damage awards against officers and directors pursuant to these indemnification provisions.

We believe that these provisions
and the indemnity agreements are necessary to attract and retain talented and experienced officers and directors.

ADDITIONAL INFORMATION

This prospectus is part of
a Registration Statement on Form S-3 that we have filed with the SEC relating to the shares of our securities being offered hereby. This
prospectus does not contain all of the information in the Registration Statement and its exhibits. The Registration Statement, its exhibits
and the documents incorporated by reference in this prospectus and their exhibits, all contain information that is material to the offering
of the securities hereby. Whenever a reference is made in this prospectus to any of our contracts or other documents, the reference may
not be complete. You should refer to the exhibits that are a part of the Registration Statement in order to review a copy of the contract
or documents. The Registration Statement and the exhibits are available at the SEC’s website.

We file annual, quarterly
and current reports, proxy statements and other information with the SEC. The SEC maintains an Internet site at http://www.sec.gov
that contains reports, proxy and information statements, and other information regarding issuers, such as us, that file electronically
with the SEC. Additionally, you may access our filings with the SEC through our website at www.synergychc.com. We have included
our website address as an inactive textual reference only and our website and the information contained on, or that can be accessed through,
our website will not be deemed to be incorporated by reference in, and are not considered part of, this prospectus.

We will provide you without
charge, upon your oral or written request, with an electronic or paper copy of any or all reports, proxy statements and other documents
we file with the SEC, as well as any or all of the documents incorporated by reference in this prospectus (other than exhibits to such
documents unless such exhibits are specifically incorporated by reference into such documents). Requests for such copies should be directed

Synergy CHC Corp.

865 Spring Street

Westbrook, Maine 04092

You should rely only on the
information in this prospectus and the additional information described above and under the heading “Incorporation of Certain Information
by Reference” below. We have not authorized any other person to provide you with different information. If anyone provides you with
different or inconsistent information, you should not rely upon it. We are not making an offer to sell these securities in any jurisdiction
where such offer or sale is not permitted. You should assume that the information in this prospectus was accurate on the date of the front
cover of this prospectus only. Our business, financial condition, results of operations and prospects may have changed since that date.

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

The SEC allows us to “incorporate
by reference” information that we file with it into this prospectus, which means that we can disclose important information to you
by referring you to those documents. The information incorporated by reference is an important part of this prospectus. The information
incorporated by reference is considered to be a part of this prospectus, and information that we file later with the SEC will automatically
update and supersede information contained in this prospectus and any accompanying prospectus supplement.

We incorporate by reference
the documents listed below that we have previously filed with the SEC:

●	Annual Report on  Form 10-K  for
the year ended December 31, 2024 filed on March 31, 2025;

●	Those portions of our Definitive Proxy Statement on Schedule 14A
for our 2025 Annual Meeting of Stockholders filed with the SEC on April 28, 2025 that are incorporated by reference into our Annual
Report on Form 10-K for the year ended December 31, 2024;

●	Quarterly Reports on Form 10-Q
for the fiscal quarters ended March 31,
2025 , June 30, 2025 and September 30, 2025, respectively, filed on May 15, 2025 , August 14,
2025 , and November 13, 2025 , respectively;

●	Current Reports on Form 8-K (excluding
any reports or portions thereof that are deemed to be furnished and not filed) filed on  March 31,
2025 , June 4,
2025 , June 12,
2025 , June 18,
2025 , August 27, 2025 and September 22, 2025 ; and

●	Our registration statement on  Form 8-A  filed
on October 21, 2024.

All reports and other documents
that we file with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of the initial filing of the registration
statement and prior to effectiveness of the registration statement, and after the date of this prospectus but before the termination of
the offering of the securities hereunder will also be considered to be incorporated by reference into this prospectus from the date of
the filing of these reports and documents, and will supersede the information herein; provided, however, that all reports, exhibits and
other information that we “furnish” to the SEC will not be considered incorporated by reference into this prospectus. We undertake
to provide without charge to each person (including any beneficial owner) who receives a copy of this prospectus, upon written or oral
request, a copy of all of the preceding documents that are incorporated by reference (other than exhibits, unless the exhibits are specifically
incorporated by reference into these documents). You may request a copy of these materials in the manner set forth under the heading “Additional
Information,” above.

Common Stock

PROSPECTUS SUPPLEMENT

Roth Capital Partners	Bancroft
Capital LLC

December